Curcumin: Powerful Immunomodulator from Turmeric

Current Immunology Reviews

Volumn 10, Issue 2, 2014, Pages 122-132

  Cundell, Diana R ^a   Wilkinson, Frank ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

COX 2 (cyclooxygenase 2) inhibitor; Herbal medicine; NF (nuclear factor kappa beta); Phytochemical; Structure activity relationship

Indexed keywords

CURCUMIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; TURMERIC;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; ENZYME INHIBITION; HERBAL MEDICINE; HUMAN; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 84920507521     PISSN: 15733955     EISSN: 1875631X     Source Type: Journal    
DOI: 10.2174/1573395510666141029233003     Document Type: Article

References (114)

1. Darshan S, Doreswarmy R. Medicinal plant patents scenario in the era of drug development. Indian Drugs 1998; 35(2): 55-66.
2. Odwyer PJ, Leylandjones B, Alonso MT, Marsoni S, Wittes RE. Etopside (VP-16-213) Current status of an active anticancer drug. N. Engl J. Med. 1985; 312: 692-700.
3. Noble RL. The discovery of the vinca alkaloids - chemotherapeutic agents against cancer. Biochem Cell Biol 1990; 68: 1344-51.
4. Oberlies NH, Kroll DJ. Camptothecin and taxol: Historic achievements in natural products research. J Nat Prod 2004; 67: 129-135.
5. Mabberley DJ. The plant-book: a portable dictionary of the vascular plants. 2nd Ed. Cambridge University Press: Cambridge 1997.
6. Evans WC. Trease and Evans Pharmacognosy. 15th Ed, 2002, WB Saunders: Edinburgh.
7. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol 1978; 43: 86-92.
8. Kiuchi F, Goto Y, Sugimoto N, Akao N, Kondo K, Tsuda Y. Nematocidal activity of turmeric: synergistic action of curcuminoids. Chem Pharm Bull (Tokyo) 1993; 41:1640-3.
9. Vogel A, Pelletier J. Examen chimique de la racine de Curcuma. J Pharm. 1815; 1: 289-300.
10. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012; 39 (3): 283-99.
11. Schraufstatter E, Bernt H. Antibacterial action of curcumin and related compounds. Nature. 1949; 164(4167): 456.
12. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009; 30(2): 85-94.
13. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009; 41(1): 40-59.
14. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: Lessons learned from clinical trials. The AAPS Journal 2013; 15(1).
15. Loeber CC. De curcuma officinarum. diss Inaug Halae. 1748.
16. Oppenheimer A. Turmeric (curcumin) in biliary diseases. Lancet. 1937; 229: 619-21.
17. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology 1980; 16: 259-65.
18. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). Journal of Biological Chemistry 1995; 270: 24995-25000.
19. Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008; 76: 1590-611.
20. Naito M, Wu X, Nomura H, et al. The protective effects of tetrahydro-curcumin on oxidative stress in cholesterol-fed rabbits. J Atheroscler Thromb 2002; 9: 243-50.
21. Balasubramanian S, Eckert RL. Green tea polyphenol and curcumin inversely regulate human involucrin promoter activity via opposing effects on CCAAT/enhancer-binding protein function. J Biol Chem 2004; 279: 24007-14.
22. Selvam C, Jachak SM, Thilagavathi R, Chakraborti AK. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and antiinflammatory agents. Bioorg Med Chem Lett 2005; 15:1793-7.
23. Weber WM, Hunsaker LA, Roybal CN, et al. Activation of NF kappa B is inhibited by curcumin and related enones. Bioorg Med Chem 2006; 14: 2450-61.
24. Al-Omar MA, Youssef KM, El-Sherbeny MA, Awadalla SA, El- Subbagh HI. Synthesis and in vitro antioxidant activity of some new fused pyridine analogs. Arch Pharm (Weinheim) 2005; 338: 175-80.
25. Zambre AP, Kulkarni VM, Padhye S, Sandur SK, Aggarwal BB. Novel curcumin analogs targeting TNF-induced NF kappa B activation and proliferation in human leukemic KBM-5 cells. Bioorg Med Chem 2006; 14: 7196-204.
26. Shim JS, Kim DH, Jung HJ, et al. Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg Med Chem 2002; 10: 2987-92.
27. Shim JS, Lee J, Park HJ, Park SJ, Kwon HJ. A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/ calmodulin function. Chem Biol 2004; 11: 1455-63.
28. Youssef D, Nichols CE, Cameron TS, Balzarini J, De ClercqE, Jha A. Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues. Bioorg Med Chem Lett 2007; 17: 5624-9.
29. Lin L, Shi Q, Nyarko AK, Bastow KF, Wu CC, Su CY. Antitumor agents. 250. Design and synthesis of newcurcumin analogues as potential anti-prostate cancer agents. J Med Chem 2006; 49: 3963- 72.
30. Sui Z, Salto R, Li J, Craik C, Ortiz de Montellano PR. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg Med Chem 1993; 1: 415-22.
31. Pucci D, Bloise R, Bellusci A, Bernardini S, Ghedini M, Pirillo S, et al. Curcumin and cyclopalladated complexes: a recipe for bifunctional biomaterials. J Inorg Biochem 2007; 101:1013-22.
32. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-18.
33. Sou K, Inenaga S, Takeoka S, Tsuchida E. Loading of curcumin into macrophages using lipid-based nanoparticles. Int J Pharm 2008; 352: 287-93.
34. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticleencapsulated curcumin (“nanocurcumin”):a novel strategy for human cancer therapy. J. Nanobiotechnol 2007; 5: 3.
35. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Antitumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995; 94: 79-83.
36. Bruzell EM, Morisbak E, Tonnesen HH. Studies on curcumin and curcuminoids. XXIX. Photoinduced cytotoxicity of curcumin in selected aqueous preparations. Photochem Photobiol Sci 2005; 4: 523-30.
37. Liu A, Lou H, Zhao L, Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J. Pharm. Biomed. Anal 2006; 40 (3): 720-7.
38. Salmaso S, Bersani S, Semenzato A, Caliceti P. Newcyclodextrin bioconjugates for active tumour targeting. J Drug Target 2007; 15: 379-90.
39. [39] Antony B. Composition to enhance the bioavailability of curcumin US 8197869 B2.
40. ®in traditional vehicles using non-everted rat intestinal sac model. J Functional Foods 2010; 2: 60-5.
41. Brennan, P, O'Neill, LA (1998). Inhibition of nuclear factor kappaB by direct modification in whole cells--mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochem Pharmacol 1998; 55(7): 965-73.
42. Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)- mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 1998; 55: 775-83.
43. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokinemediated NF-kappa B activation and pro-inflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999; 163: 3474-83.
44. Kang G, Kong P-J, Yuh Y-J, et al. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J Pharmacol Sci 2004; 94: 325-8.
45. Moon Y, Glasgow WC, Elin TE. Curcumin suppresses interleukin 1beta-mediated microsomal prostaglandin E synthase I by altering early growth response gene 1 and other signaling pathways. Journal of Pharmacology & Experimental Therapeutics 2005; 315: 788-95.
46. Strasser E-M, Wessner B, Manhart N, Roth E. The relationship between the anti-inflammatory effects of curcumin and cellular glutathione content in myelomonocytic cells. Biochemical Pharmacology 2005; 70: 552-9.
47. Funk JL, Frye JB, Oyarzo JN, et al. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum 2006; 54: 3452-64.
48. Jung KK, Lee HS, Cho JY, et al. Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life Sciences 2006; 79: 2022-31.
49. Gilmore TD 2006. Introduction to NF-κB: players, pathways, perspectives. Oncogene 2006; 25 (51): 6680-4.
50. Fitzpatrick FA, Soberman Y. Regulated formation of eicosanoids. J Clin Invest 2001; 107(11): 1347-51.
51. Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN. The effect of turmeric extracts on inflammatory mediator production. Phytomedicine 2005; 12: 445-452.
52. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 1999; 39: 41-7.
53. Chan MM-Y. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995; 49: 1551-6.
54. Banerjee M, Tripathi LM, Srivastava VML, Puri A, Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 2003; 25: 213-24.
55. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney, AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991; 51: 813-9.
56. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5- lipoxygenase. Carcinogenesis 2004; 25: 1671-9.
57. Cho J-W, Park K, Kweon GR, et al. Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med 2005; 37: 186-92.
58. Klawitter M, Quero L, Klasen J, et al. Curcuma DMSO extracts and curcumin exhibit an anti-inflammatory and anti-catabolic effect on human intervertebral disc cells, possibly by influencing TLR2 expression and JNK activity. J Inflamm 2012; 9(1): 29.
59. Bagad AS, Joseph JA, Bhaskaran N, Agarwal A. Comparative Evaluation of Anti-Inflammatory Activity of Curcuminoids, Turmerones, and Aqueous Extract of Curcuma longa. Adv Pharmacol Sci 2013, Article ID 805756, 2013.
60. Banjerdpongchai R, Wilaira, P. Effects of water-soluble antioxidants and MAPKK/MEK inhibitor on curcumin-induced apoptosis in HL-60 human leukemic cells. Asian Pac J Cancer Prev 2005; 6: 282-5.
61. Karunagaran D, Rashmi, R Kumar, TR. Induction of apoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Targets 2005; 5: 117-29.
62. Volate SR, Davenport DM, Muga SJ, Wargovich MJ. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 2005; 26: 1450-6.
63. Shankar S, Ganapathy S, Chen Q, Srivastava RK. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 2008; 7:16.
64. Perry MC, Demeule M, Régina A, Moumdjian R, Béliveau R. Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res 2010; 54(8): 1192-2101.
65. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A, Patumraj S. Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. World J Gastroenterol 2008; 14: 2003-9.
66. Lin YG, Kunnumakkara AB, Nair A, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007; 13: 3423-30.
67. Gururaj AE, Belakavadi M, Venkatesh DA, Marmé D, Salimath BP. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 2002; 297: 934-42.
68. Mohan R, Sivak J, Ashton P, et al. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000; 275: 10405-12.
69. Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cellimplanted nude mice. Clin Hemorheol Microcirc 2006; 34: 109-15.
70. Nishida N, Yano H, Nishida T, Ymiro T, Koshida M. Angiogenesis in Cancer. Vasc Health Risk Manag 2006; 2(3): 213-9.
71. Lee KW, Kim J-H, Lee HJ Surh, Y-J. Curcumin inhibits phorbol ester-induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2phosphorylation and NFkappaB transcriptional activity in MCF10A human breast epithelial cells. Antioxidants & Redox Signaling 2005; 7: 1612-20.
72. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemo-preventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signaling complex. Oncogene 1999; 18: 6013-20.
73. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT- 29 human colon cancer cells. Cancer Letters 2001; 172: 111-8.
74. Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N. Downregulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. Journal of the Society for Integrative Oncology 2006; 4: 21-26.
75. Atsumi T, Murakami Y, Shibuya K, Tonosaki K, Fujisawa S. Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression, by curcumin and its analog, alpha-diisoeugenol. Anticancer Research 2005; 25: 4029-36.
76. Divya CS, Pillai MR. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB andAP-1 translocation, and modulation of apoptosis. Mol Carcinog 2006; 45: 320-32.
77. Lee J, Im Y-H, Jung HH, et al. Curcumin inhibits interferon-alpha induced NF-kappaB217 and COX-2 in human A549 non-small cell lung cancer cells. Biochemical & Biophysical Research Communications 2005; 334: 313-8.
78. Sharma C, Kaur J, Shishodia S, Aggarwal BB, Ralhan R. Curcumin downregulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology 2006; 228: 1-15.
79. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind pilot clinical trials of curcumin in patients with Alzheimer Disease. J Clin Psychopharmacol. 2008; 28(1): 110-3.
80. Durgaprasad S, Pai CG, Vasanthkumar, et al. A pilotstudy of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 2005; 122: 315-8.
81. Shoskes D, Lapierre C, Cruz-Corerra M, et al. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation 2005; 80: 1556-1559.
82. Prucksunand C, Indrasukhsri B, Leethochawalit M, Hungspreugs K. Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing ofpeptic ulcer. Southeast Asian J Trop Med Public Health 2001; 32: 208-215.
83. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 2004; 10: 1015-8.
84. Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo-controlled cross-over 4g study and an openlabel 8g extension study. Am J Hematol 2012; 87(5): 455-60
85. Ide H, Tokiwa S, Sakamaki K, et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 2010; 70(10): 1127-33.
86. Misra S. Randomized double blind placebo control studies, the “Gold Standard” in intervention based studies. Ind J Sex Trans Dis 2012; 33(2):131-4.
87. Jian Y-T, Mai G-F, Wang J-D, Zhang Y-L, Luo R-C, Fang Y-X. Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 2005; 11: 1747-52.
88. Zhang M, Deng C, Zheng J, Xia J, Sheng D. Curcumin inhibits trinitrobenzenesulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma. Int Immunopharmacol. 2006; 6(8): 1233-42
89. Salh B, Assi K, Templeman V, Parhar K, et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physio 2003; 285: G235-243.
90. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005; 50: 2191-3.
91. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502- 6.
92. Henrotin Y, Priem F, Mobasheri A. Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. SpringerPlus 2013; 2: 56
93. Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B. Treatment ofosteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol 1991; 33(1-2): 91-5.
94. ®a curcuminphosphatidylcholine complex, during extended administration in osteoarthritis patients. Alternative Med Rev: J Clin Therapeutic 2010; 15(4): 337-44.
95. Chandran B, Goel A. Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis. Phytother Res 2012; 26(11): 1719-25.
96. Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, et al. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging 2014; 9: 451-8.
97. ®) in Patients with Osteoarthritis of the Knee (Gonarthrosis). BioXtract SA. ClinicalTrials.gov Identifier: NCT00992004
98. Curcumin in Rheumatoid Arthritis, sponsored by University of California at Los Angeles. ClinicalTrials.gov Identifier: NCT00752154
99. 95®CG(Biocurcumax™), A Novel Bioenhanced Preparation of Curcumin. Ind J Pharm Sci 2008; 70(4): 445-9.
100. Benny M, Antony M. Bioavailability of BioCurcurmax™ (BCM- 095™). Spice India September 2006; 11-5.
101. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind pilot clinical trials of curcrumin in patients with Alzheimer Disease. J Clin Psychopharmacol. 2008; 28(1): 110-3.
102. Das DA, Balan A, Sreelatha KT. Comparative study of the efficacy of curcumin and turmeric as chemopreventative agents in oral submucous fibrosis: A Clinical and histopatholoogical evaluation. J Ind Acad Oral Med Radiol 2012; 22(2): 88-92.
103. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 2012; 26(11): 1719-25.
104. Lao CD, Ruffing MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complemet Altern Med 2006; 6(1): 6-10.
105. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventative agent, in patients with high risk or pre-malignant lesions. Anticancer Res 2001; 21(4B): 2895-2900.
106. Epelbaum R. Shaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010; 62(8): 1137-41.
107. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer. Clin Cancer Res 2008; 14914: 4491-9.
108. Prasad S, Aggarwal BB. Turmeric, the Golden Spice: From Traditional Medicine to Modern Medicine. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press; 2011. Chapter 13.
109. Zarghi A, Afraei S. Selective COX-2 inhibitors: A review of their structure-activity relationships. Iranian J Pharm Res 2011; 10(4): 655-83.
110. Gracy CP, Naik J, Nagarashee N. Turmeric price forecast. Agropedia 2014.
111. Baskaran P. STI: The system of turmeric intensification - an innovative method for the cultivation of turmeric. Thambal, Thambal STI Farmers’ Association 2012.
112. [112] WHO Fact Sheet Cancer. Available from http://www.who.int/mediacentre/factsheets/fs297/en/
113. Cooper GS, Bynum MLK, Somers EC. Recent Insights in the Epidemiology of Autoimmune Diseases: Improved Prevalence Estimates and Understanding of Clustering of Diseases. J Autoimmun 2009; 33(3-4): 197-207.
114. Wolf AD, Pfleger B. Burden of Major Musculoskeletal Conditions. Policy and Practice. Special Theme-Bone and Joint Decade 2000- 2010. Bull World Health Organ 2003; 81 (9): 646-56.